| CAS: | 298-57-7 | ||||||||||||||||||||||||||||
| 分子式: | C26H28N2 | ||||||||||||||||||||||||||||
| 分子量: | 368.50 | ||||||||||||||||||||||||||||
| 中文名称: |
| ||||||||||||||||||||||||||||
| 英文名称: |
| ||||||||||||||||||||||||||||
| 性质描述: | 脑益嗪盐酸盐,C26H28N2·2HCI,[7002-58-6],熔点192℃,在水中溶解度为2mg/100ml。 | ||||||||||||||||||||||||||||
| 生产方法: | 由无水哌嗪与溴代二苯甲烷制取二苯甲基哌嗪,再与苯丙烯氯缩合而得。二苯甲烷在光照下加热,滴加溴素,在130℃保温1h,即得溴代二苯甲烷,C13H11Br,[776-74-9],熔点45℃。将溴代二苯甲烷滴加到哌嗪甲苯液中,于80-90℃搅拌3h,冷却后用水洗涤反应液,再用10%稀盐酸萃取,将酸层碱化析出沉淀,过滤烘干,得二苯甲基哌嗪。将其溶解在95%乙醇中,加入碳酸钠,在65℃左右滴加苯丙烯氯,滴完后,加热回流4h,趁热过滤,滤液放置过液,析出结晶,过滤,得脑益嗪粗品,经精制,得熔点117-119℃的成品。以二苯甲烷计,总收率48.2%。 | ||||||||||||||||||||||||||||
| 用途: | 长效多功能的血管收缩拮抗剂,能扩张血管,改善血循环,预防血管脆化,可用于治疗脑血管疾病,对颈性眩晕等引起的头痛,头晕失眠、记忆力减退,偏瘫,肢体麻木无力,言语不清等症也有疗效。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||||||||||||
| C865642 | MACKLIN | 桂利嗪 | 98% | 32元/1g; 108元/5g; 355元/25g; 1164元/100g; | 展开 | ||||||||||||||||||||||||||||||||||||||
储存:2-8°C 状态:白色到几乎白色粉末到晶体 | |||||||||||||||||||||||||||||||||||||||||||
| C798233 | MACKLIN | 桂利嗪 | 10mM in DMSO | 353元/1ml; | 展开 | ||||||||||||||||||||||||||||||||||||||
储存:-20°C | |||||||||||||||||||||||||||||||||||||||||||
| C3459 | TCI | Cinnarizine | >98.0%(HPLC)(N) | 350元/10G; 1490元/50G; | 展开 | ||||||||||||||||||||||||||||||||||||||
基本信息
技术规格
物性(参考值)
| |||||||||||||||||||||||||||||||||||||||||||
| 936663 | J&K | Stugeron | 98% | 360元/100MG; | 展开 | ||||||||||||||||||||||||||||||||||||||
基本信息
安全信息
| |||||||||||||||||||||||||||||||||||||||||||
| C2180000 | Cinnarizine | European Pharmacopoeia (EP) Reference Standard | 1277.32元/ ; | 展开 | |||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. 包装 Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||
| C5270 | Sigma-Aldrich | Cinnarizine | powder | 673.54元/10 G; | 展开 | ||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 桂利嗪是哌嗪衍生物,其是从木芦苇根中提取的。它具有抗组胺和钙拮抗剂的特性。肉桂利嗪用于治疗眩晕、不稳定和认知障碍。桂利嗪具有抗胆碱能,抗 5-羟色胺能和抗多巴胺能作用。它增强脑血流量。桂利嗪可阻断平滑肌细胞的收缩,也可作为皮肤增白剂。 应用 使用全细胞电压钳技术,桂利嗪可用于阻断豚鼠耳蜗急性分离的内部毛细胞中钾电流的压力依赖性变化。它也已用在体内和体外研究中分析药物的剂量和桂利嗪的在自纳米乳化药物递送系统(SNEDDS)中的物理形式对大鼠吸收的影响。
生化/生理作用 Ca2+ 通道阻滞剂;中枢和外周血管扩张剂。 特点和优势 该化合物由 Johnson & Johnson 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单,请单击此处。 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||
| PHR2811 | Supelco | Cinnarizine | certified reference material, pharmaceutical secondary standard | 4229.56元/200 MG; | 展开 | ||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards 分析说明 These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||